Safety and efficacy of rosiglitazone in the elderly diabetic patient

References

• UK Prospective Diabetes Study GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet199835291318378539742976
   PubMed Web of Science ®Google Scholar
• ColhounHMBetteridgeDJDurringtonPNPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialLancet2004364943568569615325833
   PubMed Web of Science ®Google Scholar
• CollinsRArmitageJParishSSleighPPetoRMRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trialLancet200336193742005201612814710
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) CollaboratorsKearneyPMBlackwellLEfficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysisLancet2008371960711712518191683
   PubMed Web of Science ®Google Scholar
• GaedePVedelPLarsenNMultifactorial intervention and cardiovascular disease in patients with type 2 diabetesN Engl J Med2003348538339312556541
   PubMed Web of Science ®Google Scholar
• KannelWBLipids, diabetes, and coronary heart disease: insights from the Framingham StudyAm Heart J1985110110011074061265
   PubMed Web of Science ®Google Scholar
• SinclairAJFinucanePDiabetes in Old Age3rd EdHoboken, NJWiley1995
   Google Scholar
• NathanDMBuseJBDavidsonMBAmerican Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care200932119320318945920
   PubMed Web of Science ®Google Scholar
• Yki-JärvinenHThiazolidinedionesN Engl J Med2004351111106111815356308
   PubMed Web of Science ®Google Scholar
• ChawlaARepaJJEvansRMNuclear receptors and lipid physiology: opening the X-filesScience200129455481866187011729302
   PubMed Web of Science ®Google Scholar
• AronoffSRosenblattSBraithwaiteSEganJWMathisenALSchneiderRLPioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response studyDiabetes Care2000231605161111092281
   PubMed Web of Science ®Google Scholar
• KipnesMSKrosnickARendellMSEganJWMathisenALSchneiderRLPioglitazone hydrochloride in combination with sulfonylurea therapy improves glycaemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled studyAm J Med2001111101711448655
   PubMed Web of Science ®Google Scholar
• RaskinPRendellMRiddleMCDoleJFFreedMIRosenstockJA randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type2 diabetesDiabetes Care2001241226123211423507
   PubMed Web of Science ®Google Scholar
• FonsecaVRosenstockJPatwardhanRSalzmanAEffect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trialJAMA20002831695170210755495
   PubMed Web of Science ®Google Scholar
• IwamotoYKosakaKKuzuyaTAkanumaYShigetaYKanekoTEffects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapyDiabetes Care19961921511568718436
   PubMed Web of Science ®Google Scholar
• KumarSBoultonAJBeck-NielsenHTroglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study GroupDiabetologia1996396701709Erratum in: Diabetologia 1996;39(10):1245.8781766
   PubMedGoogle Scholar
• RosenCJThe rosiglitazone story–lessons from an FDA Advisory Committee meetingN Engl J Med2007357984484617687124
   PubMed Web of Science ®Google Scholar
• IssemannIGreenSActivation of a member of the steroid hormone receptor superfamily by peroxisome proliferatorsNature199034762946456502129546
   PubMed Web of Science ®Google Scholar
• BadrMA forum for a highly important and ever-expanding field of studyPPAR Res200620066138517259666
   PubMedGoogle Scholar
• van RaalteDHLiMPritchardPHWasanKMPeroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising futurePharm Res200492191531153815497675
   PubMed Web of Science ®Google Scholar
• WalczakRTontonozPPPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolismJ Lipid Res200243217718611861659
   PubMed Web of Science ®Google Scholar
• RosenEDWalkeyCJPuigserverPSpiegelmanBMTranscriptional regulation of adipogenesisGenes Dev200014111293130710837022
   PubMed Web of Science ®Google Scholar
• NolanJJLudvikBBeerdsenPJoyceMOlefskyJImprovement in glucose tolerance and insulin resistance in obese subjects treated with troglitazoneN Engl J Med1994331118811937935656
   PubMed Web of Science ®Google Scholar
• MiyazakiYGlassLTriplittCEffect of rosiglitazone on glucose and nonesterified fatty acid metabolism in Type 2 diabetic patientsDiabetologia2001442210221911793023
   PubMed Web of Science ®Google Scholar
• KadowakiTYamauchiTKubotaNHaraKUekiKTobeKAdiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndromeJ Clin Invest200611671784179216823476
   PubMed Web of Science ®Google Scholar
• HanSJKangESHurKYRosiglitazone inhibits early stage of glucolipotoxicity-induced beta-cell apoptosisHorm Res20087016517318663317
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study GroupEffects of intensive glucose lowering in type 2 diabetesN Engl J Med20083582545255918539917
   PubMed Web of Science ®Google Scholar
• FDA Briefing DocumentJoint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee30 July 2007. Philadelphia, PAGlaxoSmithKline2007Accessed Jan 11, 2009. Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4308b1-02-fda-backgrounder.pdf
   Google Scholar
• McAfeeATKoroCLandonJZiyadehNWalkerAMCoronary heart disease outcomes in patients receiving antidiabetic agentsPharmacoepidemiol Drug Saf20071671172517551989
   PubMed Web of Science ®Google Scholar
• GersteinHCYusufSBoschJEffect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialLancet20063681096110516997664
   PubMed Web of Science ®Google Scholar
• KahnSEHaffnerSMHeiseMAGlycemic durability of rosiglitazone, metformin, or glyburide monotherapyN Engl J Med20063552427244317145742
   PubMed Web of Science ®Google Scholar
• NissenSEWolskiKEffect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causesN Engl J Med2007356242457247117517853
   PubMed Web of Science ®Google Scholar
• HomePDPocockSJBeck-NielsenHRECORD Study GroupRosiglitazone evaluated for cardiovascular outcomes – an interim analysisN Engl J Med20073571283817551159
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKFurbergCDLong-term risk of cardiovascular events with rosiglitazone: a meta-analysisJAMA20072981189119517848653
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Study Nos. ZM2005/00181/01 and HM2006/00497/00/WEUSRTP866: Avandia Cardiovascular Event Modeling Project and Coronary Heart Disease Outcomes in Patients Receiving Antidiabetic Agents. Accessed Jan 11, 2007. Available from: http://ctr.gsk.co.uk/Summary/Rosiglitazone/III_CVmodeling.pdf
   Google Scholar
• RichterBBandeira-EchtlerEBergerhoffKClarCEbrahimSRosiglitazone for type 2 diabetes mellitusCochrane Database Syst Rev20073CD00606317636824
   PubMedGoogle Scholar
• WierzbickiASSurrogate markers, atherosclerosis and cardiovascular disease preventionInt J Clin Pract200862798198718564270
   PubMed Web of Science ®Google Scholar
• MulrowCDCornellJLocalioARRosiglitazone: a thunderstorm from scarce and fragile dataAnn Intern Med2007147858558717938398
   PubMedGoogle Scholar
• LipscombeLLGomesTLévesqueLEHuxJEJuurlinkDNAlterDAThiazolidinediones and cardiovascular outcomes in older patients with diabetesJAMA2007298222634264318073359
   PubMed Web of Science ®Google Scholar
• WinkelmayerWCSetoguchiSLevinRSolomonDHComparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapyArch Intern Med2008168212368237519029503
   PubMed Web of Science ®Google Scholar
• DormandyJACharbonnelBEcklandDJSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trialLancet200536694931279128916214598
   PubMed Web of Science ®Google Scholar
• LincoffAMWolskiKNichollsSJNissenSEPioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trialsJAMA2007298101180118817848652
   PubMed Web of Science ®Google Scholar
• MannucciEMonamiMLamannaCGensiniGFMarchionniNPioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trialsDiabetes Obes Metab200810121221123818505403
   PubMed Web of Science ®Google Scholar
• GoldbergRBKendallDMDeegMAGLAI Study InvestigatorsA comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemiaDiabetes Care20052871547155415983299
   PubMed Web of Science ®Google Scholar
• DeegMABuseJBGoldbergRBGLAI Study InvestigatorsPioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemiaDiabetes Care200730102458246417595355
   PubMed Web of Science ®Google Scholar
• DeegMATanMHPioglitazone versus rosiglitazone: Effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studiesPPAR Res2008200852046518769492
   PubMed Web of Science ®Google Scholar
• HsiaoAWorrallDSOlefskyJMSubramaniamSVariance-modeled posterior inference of microarrray data: detecting gene-expression changes in 3T3-L1 adipocytesBioinformatics200420173108312715217816
   PubMed Web of Science ®Google Scholar
• European Agency for the Evaluation of Medicinal Products (EMEA)EPARS for authorised medicinal products for human useLondon, UKAvandia2007Accessed Jan 11, 2009. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/avandia/avandia.htm
   Google Scholar
• NestoRWBellDBonowROThiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes AssociationDiabetes Care20042725626314693998
   PubMedGoogle Scholar
• SinghSLokeYKFurbergCDThiazolidinediones and heart failure: a teleo-analysisDiabetes Care2007302148215317536074
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKFurbergCDLong-term risk of cardiovascular events with rosiglitazone: a meta-analysisJAMA2007298101189119517848653
   PubMed Web of Science ®Google Scholar
• SchwartzAVSellmeyerDEVittinghoffEThiazolidinedione use and bone loss in older diabetic adultsJ Clin Endocrinol Metab20069193349335416608888
   PubMed Web of Science ®Google Scholar
• Takeda Pharmaceuticals. Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS® (pioglitazone HCl) tablets for type 2 diabetes mellitus. March 2007. Accessed on Jan 11, 2009. Available from: http://www.fda.gov/medwatch/safety/2007/Actosmar0807.pdf
   Google Scholar
• LokeYKSinghSFurbergCLong-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysisCMAJ20091801323919073651
   PubMed Web of Science ®Google Scholar
• GreyABollandMGambleGThe peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trialClin Endocrinol Metab200792413051310
   Google Scholar
• GlintborgDAndersenMHagenCHeickendorffLHermannAPAssociation of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trialJ Clin Endocrinol Metab20089351696170118285411
   PubMed Web of Science ®Google Scholar
• AliAAWeinsteinRSStewartSAParfittAMManolagasSCJilkaRLRosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formationEndocrinology20051461226123515591153
   PubMed Web of Science ®Google Scholar
• LipscombeLLThiazolidinediones: Do harms outweigh benefitsCMAJ2009180161719073650
   PubMedGoogle Scholar